JACC: CASE REPORTS © 2020 PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/).

CASE REPORT

EDITOR'S HIGHLIGHTS

Iron Deficiency Anemia-Induced Cardiomyopathy With Congestive Heart Failure





Reversible Cardiac Dysfunction Assessed by Multi-Imaging Modalities

Shiro Miura, MD, MSc,^a Masanao Naya, MD, PнD,^b Takehiro Yamashita, MD, PнD^a

ABSTRACT

Iron deficiency anemia (IDA) can cause left ventricular (LV) dysfunction, causing heart failure. A 48-year-old woman with severe IDA developed congestive heart failure that was properly diagnosed, managed, and followed with multiple imaging modalities to explore potential mechanisms, highlighting the reversibility of LV function in unique cardiomyopathy. (Level of Difficulty: Intermediate.) (J Am Coll Cardiol Case Rep 2020;2:1806-11) © 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Severe iron deficiency anemia (IDA) has been reported to play a pivotal role in the development of heart failure (HF) through left ventricular (LV) dysfunction and myocardial damage, and substantial clinical benefits have been found as a

LEARNING OBJECTIVES

- IDA-induced cardiomyopathy can be characterized by severe chronic anemia, significant microvascular dysfunction, and high-output HF, which is reversible if treated properly.
- Multi-imaging modalities such as transthoracic echocardiography, CMR, coronary angiography with hemodynamics measurements, and cardiac positron emission tomography can improve accurate diagnosis and appropriate management.

result of iron deficiency treatment even without anemia (1). A remarkable feature of IDA-induced HF may be the reversibility of LV dysfunction with appropriate treatment. However, the pathogenesis of cardiomyopathy associated with IDA is unknown due to the limited number of affected patients. Here, we report an impressive case with severe IDA causing LV dysfunction and congestive HF, which was appropriately diagnosed and managed. The patient was followed up with multiple imaging modalities exploring the potential mechanisms of IDA-induced HF in terms of myocardial tissue characteristics and myocardial blood flow.

HISTORY OF PRESENTATION

A 48-year-old woman presented with chronic leg edema and worsening exertional dyspnea. She also

Manuscript received June 18, 2020; revised manuscript received July 15, 2020, accepted July 22, 2020.

From the ^aDepartment of Cardiology, Hokkaido Ohno Memorial Hospital, Sapporo, Japan; and the ^bDepartment of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the *JACC: Case Reports* author instructions page.

complained of menorrhagia with irregular periods more than 6 months ago. Vital sign measurements showed blood pressure of 107/48 mm Hg, heart rate of 81 beats/min, SpO₂ of 94% (room), and temperature of 36.9°C. Physical examination revealed marked pallor of the skin and conjunctiva, jugular vein distention, crackles in both lungs, rapid regular heart rhythm without any murmur, palpable spleen, and pitting edema of both lower extremities. Electrocardiogram showed normal sinus rhythm with horizontal ST depression in the limb leads (Figure 1A). Chest radiography revealed marked cardiomegaly and mild pulmonary congestion (Figure 1B). The initial hemoglobin level was 1.7 g/l, hematocrit level was 7.2%, and mean corpuscular volume was 55 fl. Iron parameters suggested severe IDA with an iron level of 8 μ g/dl, total iron-binding capacity of 468 μ g/dl, and ferritin level of 2 ng/ml. The rest of the blood test results and coagulation times, along with other laboratory tests, including clinical chemistry, renal, liver, and thyroid function, were normal except for an elevated level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) (1,547 pg/ml). Stool guaiac tests were negative. The patient received three units of packed red blood cells in 4 days and was admitted for evaluation and treatment of severe IDA and HF.

PAST MEDICAL HISTORY

The patient's medical history was unremarkable except for that she regularly smoked tobacco and consumed alcohol.

DIFFERENTIAL DIAGNOSES

The patient showed high-output HF with a high cardiac index and low systemic vascular resistance. Chronic high-output HF was explained by severe anemia after excluding other common causes, such as obesity, thyroid disease, arteriovenous shunts, and lung and liver diseases. By characterizing myocardial tissue, cardiac magnetic resonance (CMR) helped to distinguish secondary etiologies, such as myocarditis, amyloidosis, sarcoidosis, noncompaction cardiomyopathy, and dilated phase hypertrophic cardiomyopathy. ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/ CT) was useful in excluding myocarditis and sarcoidosis. Last, her benign clinical course, which was shortly controlled with iron replacement and transfusion of packed red blood cells, was more suggestive of HF due to severe IDA.

ABBREVIATIONS AND ACRONYMS

¹⁸F-FDG = ¹⁸Ffluorodeoxyglucose

CMR = cardiac magnetic resonance

HF = heart failure

IDA = iron deficiency anemia

LV = left ventricular

NT-proBNP = N-terminal pro-B-type natriuretic peptide

PET/CT = positron emission tomography/computed tomography



FIGURE 2 Initial and Follow-Up TTE and Coronary Angiography





Initial transthoracic echocardiogram (TTE) (A) exhibiting biventricular dilatation with preserved left ventricular (LV) wall thickness on a short-axis view compared with the 4-month follow-up TTE (B), which displayed a significant reduction in LV size and an improvement in LV contractility. LV end-diastolic diameter, LV ejection fraction, and stroke volume measured using Doppler ultrasound changed from 72 mm, 50%, and 103 ml, respectively, to 53 mm, 68%, and 67 ml, respectively, over 4 months. Coronary angiography (C) revealed no obstructive coronary disease.

INVESTIGATIONS

Initial transthoracic echocardiography showed a massively dilated LV chamber and left atrium with eccentric LV hypertrophy and trivial pericardial effusion (Figures 2A and 2B). On the seventh hospital day, coronary angiography (Figure 2C) revealed non-obstructive coronary arteries, and pressure studies were performed to assess LV end-diastolic pressure (9 mm Hg) and mean pulmonary capillary wedge pressures (9 mm Hg) with increased cardiac output at 9.0 l/min and systemic vascular resistance at 691 dynes/s/cm⁻⁵. Endomyocardial biopsy was avoided to prevent bleeding complications. CMR demonstrated biventricular dilatation and diffusely reduced LV wall motion with preserved wall thickness and absence of

late gadolinium enhancement (Figures 3A to 3C). On day 12, PET/CT with ¹³N-ammonia (Figures 4A to 4C) demonstrated that ATP-induced stress myocardial blood flow was globally low with a considerable drop in the global coronary flow reserve to 1.70. Moreover, ¹⁸F-FDG-PET/CT detected abnormally high ¹⁸F-FDG uptake in the uterus with no metastases (Figure 5). Finally, the patient was referred to our obstetrics and gynecology department where the solid mass in her uterus was diagnosed as endometrioid cancer on histology.

MANAGEMENT

Frusemide and enalapril were commenced, and the patient was gradually weaned from supplemental



CMR studies at the 4-month visit were repeated with the corresponding images (**D** to **F**). Concentric left ventricular (LV) hypertrophy and biventricular enlargement were visible with a reduced LV ejection fraction of 32%, which improved to 47% over 4 months with a significant drop in the LV end-diastolic volume from 184 to 96 ml. Late gadolinium enhancement was not present over the entire myocardium at both the acute (**C**) and follow-up phases (**F**).

oxygen. After the blood transfusion, she was treated with 7-day intravenous saccharated ferric oxide, followed by oral sulfate. At 3 weeks after discharge, she underwent a total hysterectomy with bilateral salpingo-oophorectomy at a university hospital; endometrial carcinoma was confirmed on pathological examination. At the 4-month follow-up visit, she was free of symptoms, where ST changes on electrocardiogram were normal with a normal cardiac silhouette on the chest radiograph (Figures 1C and 1D). Her LV ejection fraction improved to 69%, and LV diastolic dimension was still enlarged (54 mm) with a mildly elevated LV mass index of 111 g/m^2 (Figure 2B). Serum hemoglobin, iron, ferritin, and NT-proBNP levels were within the normal range. Repeated CMR demonstrated that biventricular dilatation improved

along with global LV wall motion, and late gadolinium enhancement was absent throughout the entire myocardium (Figures 3D to 3F). Perfusion PET/CT revealed a total recovery of global coronary flow reserve from 1.70 to 2.88 (Figures 4D to 4F).

DISCUSSION

We report a case of a middle-aged woman with chronic severe anemia and iron deficiency. We utilized novel imaging modalities to elucidate the potential mechanisms causing unique HF. Not only can progressive HF cause iron deficiency, but the converse can also occur. Iron deficiency can promote the remodeling of cardiomyocytes (2). Iron has roles beyond oxygen transport, including in the normal descending; LCX = left circumflex; RCA = right coronary artery; SA = short-axis; VLA = vertical long-axis.





Fluorodeoxyglucose (FDG)-positron emission tomography (PET) (A) dedicated cardiac and whole-body imaging with a high-fat, low-carbohydrate, protein-preferred diet in the fasting state revealed no focal FDG uptake in the myocardium (B). Abnormally high FDG uptake was detected in the uterus with no metastatic sites (C). activity of key enzymes of the citric acid cycle and reactive oxygen species scavenging enzymes. Decreased levels of reactive oxygen species scavenging enzymes in myocardial iron deficiency may intensify local oxidative stress, causing myocardial damage (3). As noted earlier, compromised oxygen delivery capacity may cause chronic tissue hypoxemia, which can lead to cardiomyocyte dysfunction. In our case, the initial perfusion PET/CT revealed significant microvascular dysfunction that may reflect global myocyte dysfunction. Moreover, IDA-induced cardiomyopathy had no association with myocardial inflammation, as shown by ¹⁸F-FDG-PET/CT.

A further remarkable aspect of the present case is the reversibility of IDA-induced cardiomyopathy confirmed with several imaging modalities. At the 4month follow-up, when the patient was asymptomatic and her hemoglobin, iron, and NT-proBNP levels were normalized, we found remarkable improvements in cardiac function parameters assessed by transthoracic echocardiography, CMR, and perfusion PET/CT. This strongly suggests that IDA-induced cardiomyopathy may be almost completely reversible. However, it remains unclear whether complete normalization of LV function occurs in severe cases. Our present case showed that the LV remained slightly dilated after HF improvement, and these findings were in line with cardiac indexes measured by CMR imaging. Close observation to evaluate longer-term cardiac function and prognosis is warranted.

FOLLOW-UP

The patient continues to take enalapril. LV function by follow-up echocardiography and hemoglobin level are within normal ranges 12 months after hospitalization.

CONCLUSIONS

To our knowledge, this is the first case of severe IDA leading to LV dysfunction and congestive HF that was properly diagnosed, managed, and followed with multiple imaging modalities to explore the potential mechanisms. This case supports the reversibility of IDA-induced cardiomyopathy if treated properly, but further research is required to determine the level of improvement.

ADDRESS FOR CORRESPONDENCE: Dr. Shiro Miura, Department of Cardiology, Hokkaido Ohno Memorial Hospital, 2-1-16-1 Miyanosawa, Nishi-ku, Sapporo 063-0052, Japan. E-mail: s.miura@ohno-kinen.or.jp.

REFERENCES

1. Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in heart failure: still relevant? J Am Coll Cardiol HF 2018;6:201-8.

2. Jankowska EA, Ponikowski P. Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin 2010;6:295-304.

3. Dai DF, Johnson SC, Villarin JJ, et al. Mitochondrial oxidative stress mediates angiotensin IIinduced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res 2011;108:837-46.

KEY WORDS cardiac magnetic resonance, cardiomyopathy, iron deficiency anemia, positron emission tomography